Katie Pandolfo Named G.M. of L.A.'s Crypto.com Arena
Pandolfo comes from another AEG property, Dignity Health Sports Park in nearby Carson, where she also served as G.M. since 2009 after starting there in 2004.
More from The Hollywood Reporter
Weezer Bassist Scott Shriner's Wife Shot During L.A. Police Chase, Authorities Say
Minivan Crashes Into Crowd Near Downtown Los Angeles' Fashion District, Injuring Nine Pedestrians
Papa Roach Marks 25th Anniversary With L.A. Concert: "It's a Celebration of Life"
During her tenure, the 125-acre campus — host of Los Angeles Galaxy MLS matches — hosted seven MLS Cup championship contests, Olympic and World Cup qualifying soccer matches, three seasons of Los Angeles Chargers NFL football (while SoFi Stadium was being built) and championship boxing.
Pandolfo will oversee day-to-day operations of the busy Crypto.com Arena and report directly to AEG president and CEO Dan Beckerman.
'Katie brings a wealth of experience to this role having guided the operations and management of Dignity Health Sports Park for over two decades,' Beckerman said in a statement. 'She is a talented leader with a proven track record of success in delivering world class events and an incredible reputation for guiding and motivating her team.'
'Her dedication and passion will be invaluable assets in leading Crypto.com Arena into the future, especially as the arena continues to build its legacy as a premier sports and entertainment destination with high-profile global events on the horizon, including the 2026 Grammy Awards, the 2027 NCAA regional men's basketball tournament and the 2028 Olympic and Paralympic games.'
Pandolfo takes over for the retiring Lee Zeidman on June 1. Zeidman, who has served as G.M. of Crypto.com Arena since the building opened in October 1999 as Staples Center, will remain as an adviser during a transition period.
'Lee has made an indelible and lasting impact on AEG, Crypto.com Arena and the city of Los Angeles, and his retirement later this year will mark the end of a remarkable chapter in his career,' Beckerman noted. 'I am grateful for Lee's friendship and support over these many years and wholeheartedly thank him for his years of leadership and numerous contributions.'
Pandolfo is a founding member of the Women's Leadership Council at AEG and serves on the L.A. Sports and Entertainment Commission and the City of Carson's Economic Development Commission.
With the promotion, Pandolfo — who was raised in Chicago and worked for the Los Angeles Dodgers after graduating from St. Norbert College in Wisconsin — will become the rare sports exec to have experience working with teams from the MLB, NFL, MLS, NHL and NBA.
'I am excited to join the talented team at Crypto.com Arena and look forward to collaborating with the arena's management team and partners to continue delivering exceptional experiences that shape the future of culture and entertainment,' she said.
Best of The Hollywood Reporter
Hollywood's Most Notable Deaths of 2025
Most Anticipated Concert Tours of 2025: Beyoncé, Billie Eilish, Kendrick Lamar & SZA, Sabrina Carpenter and More
Hollywood's Highest-Profile Harris Endorsements: Taylor Swift, George Clooney, Bruce Springsteen and More
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
Genflow Biosciences PLC Announces Company Update on Dog Trials
Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported LONDON, UK / ACCESS Newswire / August 18, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ('Genflow' or 'the Company'), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026. The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment. Study objectives are to: 1. Confirm feasibility of GF-1004 administration in the target population. 2. Validate safety and efficacy at the proposed administered dose. 3. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including: Translational Potential Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics. Dr. Eric Leire, CEO of Genflow, commented: 'Now that all dogs have received the treatment without any adverse events, we've taken an important step in confirming the treatment's safety profile. We are fully focused on advancing GF-1004 to secure a partnership with an animal health company, combining scientific and commercial expertise to pave the way for a new class of therapeutic medicines for dogs. Our shared goal is to extend the healthspan of dogs, and we believe this study will demonstrate the safety and potential efficacy of GF-1004 while opening the door to broader applications of our proprietary platform in age-related diseases in both companion animals and, ultimately, in humans.' Contacts About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. DISCLAIMER The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words 'anticipate', 'believe', 'continue', 'could', 'estimate', 'expect', 'intend', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would' and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Genflow Biosciences PLC press release
Yahoo
an hour ago
- Yahoo
Williams sympathises with Scotland's contract woes
Women's Rugby World Cup 2025: Scotland v Wales Venue: Salford Community Stadium Date: Saturday, 23 August Kick-off: 14:45 BST Coverage: Live on BBC One, BBC iPlayer, BBC Sport Online and BBC Sounds Wales co-captain Kate Williams says she sympathises with Scotland players who are going through contract uncertainty in the build up to the Rugby World Cup. More than half of Scotland's squad fear being left without a professional deal after the tournament in October. A source in their camp told the BBC in June players were suffering with their mental and emotional health. Wales experienced similar upheaval last year when they were given ultimatums and threatened with being withdrawn from the World Cup when contract talks broke down. The Welsh Rugby Union (WRU) later apologised for its handling of the situation. "I wouldn't wish what we went through on any other team," said back-row forward Williams. Callender raring to go for Wales after World Cup injury scare Wales' sisters doing it for themselves (and Nant) Scotland are due to meet Wales in their Pool B opener on Saturday. It is a game which could decide which team makes it through to the quarter-finals, with Canada expected to top the group and both sides tipped to beat Fiji. "I think it's really poor timing for them, that they're going through this now," said Williams. "I guess our timing was possibly a bit better," she added, with Wales' woes coming prior to WXV2 rather than the World Cup. And while Williams says she and her team mates "feel their pain", there will be no time for sympathy in Salford. "We are here to play rugby and we're here to win that Test match," said the Gloucester-Hartpury flanker. "We know how important it is, so it's just going to be who's better on the day."
Yahoo
2 hours ago
- Yahoo
Bulls would have won '3 or 4' titles with healthy Derrick Rose, says star
Bulls would have won '3 or 4' titles with healthy Derrick Rose, says star originally appeared on The Sporting News A former Chicago Bulls standout is convinced his old team could have won multiple championships had MVP point guard Derrick Rose avoid his the ACL and meniscus tears that permanently altered his health trajectory. MORE NEWS:Insider roasts Bulls after NBA national broadcast schedule drop During an interview with Matt Peck of the "CHGO Bulls" podcast, former two-time All-Star power forward Carlos Boozer asserted that his talented Chicago teams could have gone all the way. "You can't replace a Derrick Rose, man. Let's be honest," Boozer said. "This guy was one in a million, one in a lifetime, to be honest. If he doesn't get hurt, he retires with three or four championships and obviously first ballot Hall of Famer. That's how much influence he had on the game of basketball and that also speaks to his talent level." Boozer was something of a consolation prize free agent signing for the Bulls in 2010, when LeBron James, Dwyane Wade, Chris Bosh, and likely Joe Johnson all signed elsewhere. A prolific post scorer in his day (he didn't have much of a jumper beyond the arc, but in his era that wasn't a dealbreaker yet), Boozer was a consistent double-double machine — although he never matched his All-Star prime with the Utah Jazz while in town. Chicago ultimately amnestied him in the summer of 2014. Across his four seasons with the Bulls, Boozer averaged 15.5 points on 49.1 percent shooting from the floor and 72.4 percent shooting from the foul line, 9.0 rebounds, 2.0 assists and 0.8 steals a night. "Think about his career, right?" Boozer added. "He's from Chicago, No. 1 pick in the NBA draft. Rookie of the Year that year. Second year, becomes an All-Star. Third year, becomes the MVP... His trajectory was off the charts." MORE NEWS:Bulls' $36 million guard predicted to be among biggest names dealt at 2026 trade deadline
